Genitourinary symptoms in women with breast cancer: what do oncology health professionals think and do about them?
- 11 May 2021
- journal article
- research article
- Published by Springer Nature in Breast Cancer
- Vol. 28 (6) , 1243-1251
Abstract
Objectives We aimed to improve understanding of health professional knowledge and management of genitourinary symptoms (GUS) in women with early breast cancer (EBC). Methods A survey was sent to 872 health professionals caring for women with EBC. Questions addressed most common GUS seen, experience treating GUS, and attitudes to treatment options. Results 144 surveys were completed. Respondent characteristics: median age 50 years; 76% female; 42% medical oncologists; 24% nurses; 20% breast surgeons; 8% radiation oncologists. Most (68%) reported prescribing endocrine therapies for EBC, 99% were aware endocrine therapies can cause GUS, and 55% reported “often” or “always” asking patients on endocrine therapy if they have GUS. Respondents thought vaginal dryness was the most bothersome symptom for their patients (66%), followed by dyspareunia (11%). 81% of respondents reported seeing women stop endocrine therapy prematurely due to GUS. Respondents reported receiving “none” (19%) or “a little” (46%) training or education in managing GUS and only 16% reported feeling “very confident” managing GUS. The proportions of respondents reporting “often” and “very often” recommending the following vaginal treatments were: lubricants (81%); moisturisers (68%); oestrogens (21%); and laser (3%). Vaginal oestrogens were considered “safe” or “probably safe” by 77% and 90% of respondents for women with hormone receptor positive and negative EBC, respectively. Conclusions Despite health professionals frequently encountering GUS in women with EBC and seeing patients stop endocrine therapies prematurely, only 16% felt confident managing these symptoms. Education and training for health professionals are needed to better address this common problem.Keywords
This publication has 29 references indexed in Scilit:
- Atrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship IssueJournal of Personalized Medicine, 2015
- Sexual function after fractional microablative CO2laser in women with vulvovaginal atrophyClimacteric, 2014
- Genitourinary syndrome of menopauseMenopause, 2014
- Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical studyBreast Cancer Research and Treatment, 2014
- Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case–control studyBreast Cancer Research and Treatment, 2012
- A Self-Report Instrument That Describes Urogenital Atrophy Symptoms in Breast Cancer SurvivorsWestern Journal of Nursing Research, 2010
- Prevalence and Severity of Urogenital Symptoms in Postmenopausal Women Receiving Endocrine Therapy for Breast CancerClinical Breast Cancer, 2009
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Quality of Life of Postmenopausal Women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer TrialJournal of Clinical Oncology, 2004
- A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancerClimacteric, 2003